Periorbital filler should not be dissolved automatically before blepharoplasty. The decision depends on the material, injection plane, symptoms, ultrasound findings and whether the filler prevents a reliable assessment of the eyelid–cheek junction. Observation, targeted hyaluronidase and staged reassessment are all valid options in different situations.
First identify what was injected
Hyaluronidase acts on hyaluronic acid. It does not remove PMMA, silicone, calcium hydroxylapatite, poly-L-lactic acid, transferred fat or most other biostimulatory products. Product names, dates, amounts, injection sites and previous attempts at dissolution should be documented.
When records are incomplete, the examination alone may not identify the material or its depth. Dermatologic ultrasound can help map residual product, edema, fibrosis and altered planes.
When ultrasound changes the plan
A clinical study of 191 patients with prior periorbital treatments found distinguishable ultrasound patterns for hyaluronic acid, silicone oil, fat and several other materials. Ultrasound can show where material lies and whether findings such as fluid, calcification or increased blood flow are present.
Imaging has limits. It may not determine every product with certainty, and a visible deposit is not automatically the cause of the patient’s concern. Orbital fat, festoons, malar edema, lymphatic anatomy, allergy and systemic disease remain part of the differential diagnosis.
| Clinical situation | Possible next step | Reason |
|---|---|---|
| Unknown material or plane | Records and dermatologic ultrasound | Avoids blind hyaluronidase or incorrect assumptions |
| Known hyaluronic acid with edema or distortion | Targeted hyaluronidase and reassessment | Clarifies the underlying anatomy |
| Stable filler outside the surgical concern | Observation may be appropriate | Routine dissolution may add no benefit |
| Permanent filler or biostimulator | Individualized surgical planning | Hyaluronidase will not remove the material |
| Festoons without relevant hyaluronic acid | Separate diagnostic pathway | Blepharoplasty or hyaluronidase is not a universal solution |
When hyaluronidase may be useful
Targeted treatment may be considered when known hyaluronic acid contributes to persistent edema, a visible bulge, blue-gray discoloration, contour distortion or an unreliable lid–cheek examination. A duplex-ultrasound case series of 17 patients linked some cases of filler-related malar edema to veno-lymphatic compression and documented clinical improvement after ultrasound-guided removal.
This small series supports a mechanism in selected cases; it does not prove that all malar edema is caused by filler. The product’s cross-linking, volume, depth and tissue response influence the amount of enzyme required and the likelihood of recurrence.
Why “dissolve everything” is not a neutral decision
Hyaluronidase may cause bruising, swelling, pain, contour change and allergic reaction. Removing filler can expose a pre-existing hollow or reveal volume loss that was previously masked. Treatment may need to be staged so that inflammation settles before the anatomy is reassessed.
A retrospective study of 54 patients reported improvement after a single high-dose session, but the dosing protocol was empirical, follow-up varied widely and most patients subsequently underwent lower-eyelid blepharoplasty. The study should not be converted into a universal dose or a guarantee of complete removal.
How this fits Hybrid Blepharoplasty
Dr. June’s Hybrid Blepharoplasty distinguishes upper-lid skin excess, brow descent, true ptosis, orbital bags, lower-lid support, hollowing, malar edema, festoons and skin quality. The lower eyelid is generally approached transconjunctivally when internal fat treatment is indicated. Cantopexy, microfat, nanofat and resurfacing remain selective components.
Dissolving filler does not determine which surgery follows. Once the tissues settle, the examination may show that the main issue is a bag, a hollow, lid laxity, midface descent or edema that surgery cannot fully correct.
There is no universal waiting period
Surgery is considered when inflammation, edema and contour are stable enough for a reliable examination. Timing varies with the initial problem, amount treated, reaction and need for more than one session. A fixed number of days cannot replace reassessment.
Planning from outside Brazil
International patients should submit injection records and photographs early. Imaging, targeted treatment and reassessment may need to occur before travel or require an additional visit. Major facial surgery is performed at Hospital São José. The concierge team assists with logistics, while clinical decisions remain with the medical team.
Questions to answer before blepharoplasty
- What product was injected, where and when?
- Is the material contributing to edema or distortion?
- Would ultrasound change the diagnosis?
- Can hyaluronidase act on this material?
- Has the tissue stabilized enough for surgical planning?
- Which concern will remain even after dissolution?
